Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL551840 | 1.00 | BAZ2B (0.54) | BAZ2BNPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL551169 | 1.00 | BAZ2B (0.54) | BAZ2BNPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL14454769 | 0.80 | NPC1 (0.57) | BAZ2BNPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL5582649 | 0.80 | NPC1 (0.57) | BAZ2BNPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL5582652 | 0.80 | NPC1 (0.57) | BAZ2BNPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL5582762 | 0.80 | NPC1 (0.56) | BAZ2BNPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL5582666 | 0.79 | NPC1 (0.56) | BAZ2BNPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL30612407 | 0.79 | NPC1 (0.56) | BAZ2BNPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL30612402 | 0.79 | NPC1 (0.56) | BAZ2BNPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL5582851 | 0.79 | BAZ2B (0.57) | BAZ2BNPC1RAB9AKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035131-A1 | PYRAZOLINE COMPOUNDS | PFIZER INC | 2012-02-09 | — | — | US | disclosed |
| US-20120035131-A1 | PYRAZOLINE COMPOUNDS | PFIZER INC | 2012-02-09 | — | — | US | disclosed |
| US-20120035131-A1 | PYRAZOLINE COMPOUNDS | PFIZER INC | 2012-02-09 | — | — | US | disclosed |
| EP-2089367-B1 | PYRAZOLINE COMPOUNDS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2011-12-14 | — | — | EP | disclosed |
| EP-2089367-B1 | PYRAZOLINE COMPOUNDS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2011-12-14 | — | — | EP | disclosed |
| US-20100280016-A1 | PYRAZOLINE COMPOUNDS | PFIZER INC | 2010-11-04 | — | — | US | disclosed |
| US-20100280016-A1 | PYRAZOLINE COMPOUNDS | PFIZER INC | 2010-11-04 | — | — | US | disclosed |
| US-20100280016-A1 | PYRAZOLINE COMPOUNDS | PFIZER INC | 2010-11-04 | — | — | US | disclosed |
| US-7781428-B2 | Cardiovascular disorders; liver disorders ; vascular system disorders; antiinflammatory agents; analgesics ; edema; hypotensive agents | PFIZER INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-7781428-B2 | Cardiovascular disorders; liver disorders ; vascular system disorders; antiinflammatory agents; analgesics ; edema; hypotensive agents | PFIZER INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-7781428-B2 | Cardiovascular disorders; liver disorders ; vascular system disorders; antiinflammatory agents; analgesics ; edema; hypotensive agents | PFIZER INC. (US) | 2010-08-24 | — | — | US | disclosed |
| EP-2089367-A1 | PYRAZOLINE COMPOUNDS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2009-08-19 | — | — | EP | disclosed |
| US-20080167294-A1 | Cardiovascular disorders; liver disorders ; vascular system disorders; antiinflammatory agents; analgesics ; edema; hypotensive agents | PFIZER, INC (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080167294-A1 | Cardiovascular disorders; liver disorders ; vascular system disorders; antiinflammatory agents; analgesics ; edema; hypotensive agents | PFIZER, INC (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080167294-A1 | Cardiovascular disorders; liver disorders ; vascular system disorders; antiinflammatory agents; analgesics ; edema; hypotensive agents | PFIZER, INC (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2008053300-A1 | PYRAZOLINE COMPOUNDS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008053300-A1 | PYRAZOLINE COMPOUNDS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035131-A1 | PYRAZOLINE COMPOUNDS | F12, CYP3A7, ABCG2 | BAZ2B 908/4885NPC1 1303/4885RAB9A 188/4885 |
| US-20100280016-A1 | PYRAZOLINE COMPOUNDS | F12, CYP3A7, ABCG2 | BAZ2B 908/4885NPC1 1303/4885RAB9A 188/4885 |
| US-20080167294-A1 | Cardiovascular disorders; liver disorders ; vascular system disorders; antiinflammatory agents; analgesics ; edema; hypotensive agents | REN, F3, EDNRB | BAZ2B 4339/4885NPC1 2108/4885RAB9A 1452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.